---
annotation-target: blood.2022017257.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-22T01:31:17.088Z","updated":"2022-09-22T01:31:17.088Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":12024,"end":12075},{"type":"TextQuoteSelector","exact":"vaccinated patients with hematologic 1 malignancies","prefix":"022 1  Breakthrough COVID-19 in ","suffix":": results from EPICOVIDEHA surve"}]}]}
>```
>%%
>*%%PREFIX%%022 1  Breakthrough COVID-19 in%%HIGHLIGHT%% ==vaccinated patients with hematologic 1 malignancies== %%POSTFIX%%: results from EPICOVIDEHA surve*
>%%LINK%%[[#^sco16gldgef|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sco16gldgef


>%%
>```annotation-json
>{"created":"2022-09-22T01:32:18.846Z","updated":"2022-09-22T01:32:18.846Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":30461,"end":30549},{"type":"TextQuoteSelector","exact":"Mortality rate in hematologic malignancy patients with breakthrough COVID-19 is about 9%","prefix":"mber 2022 10  Key points 217 •  ","suffix":", 218 lower than in the pre-vacc"}]}]}
>```
>%%
>*%%PREFIX%%mber 2022 10  Key points 217 •%%HIGHLIGHT%% ==Mortality rate in hematologic malignancy patients with breakthrough COVID-19 is about 9%== %%POSTFIX%%, 218 lower than in the pre-vacc*
>%%LINK%%[[#^lpneeexy1r|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^lpneeexy1r


>%%
>```annotation-json
>{"created":"2022-09-22T01:32:25.310Z","updated":"2022-09-22T01:32:25.310Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":30614,"end":30716},{"type":"TextQuoteSelector","exact":"received monoclonal antibodies, alone or combined with antivirals, show a 220 better clinical outcome ","prefix":"nation era  219 •  Patients who ","suffix":"221 Downloaded from http://ashpu"}]}]}
>```
>%%
>*%%PREFIX%%nation era  219 •  Patients who%%HIGHLIGHT%% ==received monoclonal antibodies, alone or combined with antivirals, show a 220 better clinical outcome== %%POSTFIX%%221 Downloaded from http://ashpu*
>%%LINK%%[[#^zy6tos20tp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zy6tos20tp


>%%
>```annotation-json
>{"created":"2022-09-22T01:37:38.213Z","updated":"2022-09-22T01:37:38.213Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":31296,"end":32579},{"type":"TextQuoteSelector","exact":"A total of 1548 cases were included, mainly with lymphoid malignancies (1181 cases, 76%). 228 After viral genome sequencing in 753 cases (49%), Omicron variant was prevalent (517, 68.7%). 229 Most of the patients received at least two vaccine doses before COVID-19 (1419, 91%), mostly 230 mRNA-based (1377, 89%). Overall, 906 patients (59%) received specific treatment for COVID-19. 231 After 30-days follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in 232 patients with Omicron variant was of 7.9%, comparable to that reported for the other variants. The 233 30-day mortality rate was significantly lower than in the pre-vaccine era (31%). In the univariable 234 analysis, older age (p<0.001), active HM (p<0.001), severe and critical COVID-19 (p=0.007 and 235 p<0.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal 236 antibodies,  even  for  severe  or  critical  COVID-19,  had  a  lower  mortality  rate  (p<0.001).  In  the 237 multivariable model, older age, active disease, critical COVID-19 and at least 2-3 comorbidities 238 were correlated with a higher mortality, whereas the administration of monoclonal antibodies, alone 239 (p<0.001) or combined with antivirals (p=0.009), was observed protective.","prefix":" included in this analysis. 227 ","suffix":" 240 While mortality is signific"}]}]}
>```
>%%
>*%%PREFIX%%included in this analysis. 227%%HIGHLIGHT%% ==A total of 1548 cases were included, mainly with lymphoid malignancies (1181 cases, 76%). 228 After viral genome sequencing in 753 cases (49%), Omicron variant was prevalent (517, 68.7%). 229 Most of the patients received at least two vaccine doses before COVID-19 (1419, 91%), mostly 230 mRNA-based (1377, 89%). Overall, 906 patients (59%) received specific treatment for COVID-19. 231 After 30-days follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in 232 patients with Omicron variant was of 7.9%, comparable to that reported for the other variants. The 233 30-day mortality rate was significantly lower than in the pre-vaccine era (31%). In the univariable 234 analysis, older age (p<0.001), active HM (p<0.001), severe and critical COVID-19 (p=0.007 and 235 p<0.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal 236 antibodies,  even  for  severe  or  critical  COVID-19,  had  a  lower  mortality  rate  (p<0.001).  In  the 237 multivariable model, older age, active disease, critical COVID-19 and at least 2-3 comorbidities 238 were correlated with a higher mortality, whereas the administration of monoclonal antibodies, alone 239 (p<0.001) or combined with antivirals (p=0.009), was observed protective.== %%POSTFIX%%240 While mortality is signific*
>%%LINK%%[[#^wwgm2jdms3|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^wwgm2jdms3


>%%
>```annotation-json
>{"created":"2022-09-22T01:38:21.970Z","updated":"2022-09-22T01:38:21.970Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":33040,"end":33254},{"type":"TextQuoteSelector","exact":"Coronavirus  disease  19  (COVID-19)  is  a  life-threatening  infection  in  patients  with 245 hematologic  malignancies  (HM),  associated  with  severe  clinical  presentation  and  high  risk  of 246 death.1-3","prefix":"ember 2022 12  Introduction 244 ","suffix":"  In  April  2020,  the  Europea"}]}]}
>```
>%%
>*%%PREFIX%%ember 2022 12  Introduction 244%%HIGHLIGHT%% ==Coronavirus  disease  19  (COVID-19)  is  a  life-threatening  infection  in  patients  with 245 hematologic  malignancies  (HM),  associated  with  severe  clinical  presentation  and  high  risk  of 246 death.1-3== %%POSTFIX%%In  April  2020,  the  Europea*
>%%LINK%%[[#^d5pwwpyjemi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^d5pwwpyjemi


>%%
>```annotation-json
>{"created":"2022-09-22T01:45:22.849Z","updated":"2022-09-22T01:45:22.849Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":39392,"end":39483},{"type":"TextQuoteSelector","exact":" A  multivariable  Cox  regression  model  was 308 calculated with the Wald backward method","prefix":"  for  multivariable  analysis. ","suffix":". Mortality was analyzed by usin"}]}]}
>```
>%%
>*%%PREFIX%%for  multivariable  analysis.%%HIGHLIGHT%% ==A  multivariable  Cox  regression  model  was 308 calculated with the Wald backward method== %%POSTFIX%%. Mortality was analyzed by usin*
>%%LINK%%[[#^wsoz4k0g0wf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^wsoz4k0g0wf


>%%
>```annotation-json
>{"created":"2022-09-22T01:48:10.822Z","updated":"2022-09-22T01:48:10.822Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":49619,"end":50073},{"type":"TextQuoteSelector","exact":"In the pre-vaccination era, several studies reported a high COVID-19 mortality in HM.1-4 From 408 December 2020, anti-SARS-CoV-2 vaccines have been administered in cancer patients, including 409 those with HM.7-8 Most published studies in HMs confirmed the efficacy and safety of vaccines, 410 particularly  those  using  mRNA,  however,  most  showing  less  efficacy  in  patients  with  lymphoid 411 malignancies treated with immunosuppressive drugs.1","prefix":"ptember 2022 19  Discussion 407 ","suffix":"7-22 412 The  current  study  wa"}]}]}
>```
>%%
>*%%PREFIX%%ptember 2022 19  Discussion 407%%HIGHLIGHT%% ==In the pre-vaccination era, several studies reported a high COVID-19 mortality in HM.1-4 From 408 December 2020, anti-SARS-CoV-2 vaccines have been administered in cancer patients, including 409 those with HM.7-8 Most published studies in HMs confirmed the efficacy and safety of vaccines, 410 particularly  those  using  mRNA,  however,  most  showing  less  efficacy  in  patients  with  lymphoid 411 malignancies treated with immunosuppressive drugs.1== %%POSTFIX%%7-22 412 The  current  study  wa*
>%%LINK%%[[#^zhawxdramg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zhawxdramg


>%%
>```annotation-json
>{"created":"2022-09-22T02:02:20.894Z","updated":"2022-09-22T02:02:20.894Z","document":{"title":"blood.2022017257.pdf","link":[{"href":"urn:x-pdf:f244deec289b952e1a0c1cde3586a42e"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf"}],"documentFingerprint":"f244deec289b952e1a0c1cde3586a42e"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022017257.pdf","selector":[{"type":"TextPositionSelector","start":52677,"end":52970},{"type":"TextQuoteSelector","exact":"9 However, it is worth underlining 436 that  about  20%  of  patients  were  asymptomatic  and  SARS-CoV-2  infection  was  detected  in 437 screening programs. Interestingly, this percentage is analogous to that reported in our published 438 study  referring  to  the  pre-vaccination  era.4 ","prefix":"d to the overall population.26-2","suffix":" Unfortunately,  it  is  not  po"}]}]}
>```
>%%
>*%%PREFIX%%d to the overall population.26-2%%HIGHLIGHT%% ==9 However, it is worth underlining 436 that  about  20%  of  patients  were  asymptomatic  and  SARS-CoV-2  infection  was  detected  in 437 screening programs. Interestingly, this percentage is analogous to that reported in our published 438 study  referring  to  the  pre-vaccination  era.4== %%POSTFIX%%Unfortunately,  it  is  not  po*
>%%LINK%%[[#^zlivme987d|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zlivme987d
